XPO1 inhibition potentiates ADCC against lymphoma cells in combination with anti-CD20 monoclonal antibodies rituximab and obinutuzumab in vitro [96] and combining selinexor with ADCC inducing antibodies may lead to increased efficacy in patients. The gene discussed is XPO1; the disease is lymphoma.